Kodiak Sciences (NASDAQ:KOD) Cut to Strong Sell at Wall Street Zen

Wall Street Zen downgraded shares of Kodiak Sciences (NASDAQ:KOD) from a sell rating to a strong sell rating in a research note published on Saturday morning,Wall Street Zen reports.

Several other analysts have also recently commented on the stock. JPMorgan Chase & Co. boosted their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. The Goldman Sachs Group started coverage on Kodiak Sciences in a research report on Thursday. They issued a “neutral” rating and a $36.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Kodiak Sciences in a research note on Thursday, September 17th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $90.86.

Kodiak Sciences Stock Performance

KOD stock opened at $89.92 on Friday. Kodiak Sciences has a one year low of $10.94 and a one year high of $95.77. The company’s fifty day moving average price is $39.29 and its 200-day moving average price is $37.80. The company has a market capitalization of $5.65 billion, a PE ratio of -21.46 and a beta of 2.18.

Kodiak Sciences (NASDAQ:KOD) last issued its earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). On average, research analysts predict that Kodiak Sciences will post -3.89 EPS for the current fiscal year.

Institutional Trading of Kodiak Sciences

A number of large investors have recently made changes to their positions in the business. Engineers Gate Manager LP raised its position in shares of Kodiak Sciences by 145.8% during the 2nd quarter. Engineers Gate Manager LP now owns 29,537 shares of the company’s stock valued at $1,151,000 after buying an additional 17,520 shares in the last quarter. Squarepoint Ops LLC lifted its holdings in shares of Kodiak Sciences by 112.6% in the 2nd quarter. Squarepoint Ops LLC now owns 151,098 shares of the company’s stock valued at $5,887,000 after acquiring an additional 80,042 shares during the last quarter. Arizona State Retirement System grew its position in Kodiak Sciences by 6.9% in the second quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock worth $332,000 after acquiring an additional 554 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Kodiak Sciences in the second quarter worth about $232,000. Finally, Wellington Management Group LLP increased its stake in Kodiak Sciences by 81.9% during the second quarter. Wellington Management Group LLP now owns 793,613 shares of the company’s stock worth $30,919,000 after acquiring an additional 357,284 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

Key Stories Impacting Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Major clinical-trial success: Zenkuda and tabirafusp-ted both met their primary endpoints in the Phase 3 DAYBREAK study. The results indicated efficacy comparable to Regeneron’s established Eylea, strengthening Kodiak’s case for competing in the large wet-AMD market. Kodiak Sciences’ Zenkuda And Tabirafusp-Ted Meet Primary Endpoints In Phase 3 DAYBREAK Study For Wet AMD
• Positive Sentiment: Regulatory path advances: Kodiak plans to file for approval of Zenkuda following the trial results. A successful filing and eventual approval could transform the company from a development-stage biotech into a commercial ophthalmology company. Kodiak Sciences Stock Pops After Eye-Disease Drugs Pass Key Trial
• Positive Sentiment: Analyst estimates moved higher: Lifesci Capital raised its price target to $145 from $85 with an outperform rating; UBS lifted its target to $120 from $80 and assigned a buy rating; and HC Wainwright raised its target to $96 from $58. These revisions reflect increased expectations for Kodiak’s pipeline and commercial potential.
• Neutral Sentiment: High trading activity and bullish coverage: Trading volume was exceptionally heavy, while new coverage from Goldman Sachs and multiple reports highlighted the DAYBREAK outcome. The unusually large market reaction shows strong investor interest but also suggests elevated volatility.
• Negative Sentiment: Speculative risks remain: Traders purchased approximately 21,273 put options, far above the normal daily volume, potentially reflecting hedging or a bearish view after the sharp rally. Kodiak also remains loss-making, and the stock’s valuation now depends heavily on regulatory approval, launch execution and whether the trial results translate into durable commercial demand.

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.